VF
KAPA

Virtu Financial’s Kairos Pharma KAPA Stock Holding History

Virtu Financial’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,278
Closed -$14K – 2446
2025
Q4 		$14K Buy
+20,278
New +$19K ﹤0.01% 1479
2025
Q1 		– Sell
-13,656
Closed -$21K – 2179
2024
Q4 		$21K Sell
13,656
-19,055
-58% -$29.2K ﹤0.01% 1293
2024
Q3 		$51K Buy
+32,711
New +$66.8K ﹤0.01% 1010

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Virtu Financial's KAPA Position: Q1 2026 in Review

Virtu Financial sold out of Kairos Pharma (KAPA) in Q1 2026, closing a stake of 20,278 shares — an estimated $14K sold.

Virtu Financial first reported a position in KAPA in Q3 2024 and held it in 3 quarters. The position peaked at $51K in Q3 2024. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • Virtu Financial reported no remaining Kairos Pharma position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 20,278 Kairos Pharma shares in Q1 2026, an estimated $14K.
  • Virtu Financial first reported a position in Kairos Pharma in Q3 2024 and held it in 3 quarters.
  • Virtu Financial's Kairos Pharma position peaked at $51K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.